Blockchain Registration Transaction Record

NanoViricides Raises $2M for Broad-Spectrum Antiviral Development

NanoViricides (NNVC) announces $2M direct offering to fund broad-spectrum antiviral NV-387, which holds FDA Orphan Drug Designation for respiratory viral illnesses.

This news matters because NanoViricides is developing a revolutionary broad-spectrum antiviral, NV-387, which could become a first-line treatment for respiratory viral illnesses. The $2 million offering provides capital to advance clinical trials and regulatory approvals, potentially leading to a drug that works against multiple viruses, including COVID-19, influenza, and emerging variants. For investors, this signals continued progress in a high-impact area of biotech. For the public, it represents hope for more effective and convenient antiviral therapies that could reduce the burden of seasonal and pandemic viral outbreaks.